Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

E Ts'episang Kalafo e Ncha ea Mola oa Pele bakeng sa Kankere ea Kankere ea Gastric/GEJ Cancer

ngotsoeng ke mohlophisi

kajeno Trishula Therapeutics, Inc. kajeno e phatlalalitse liphetho tsa pele ho tsoa tekong e tsoelang pele ea Mokhahlelo oa 1 e hlahlobang TTX-030 hammoho le budigalimab (liphuputso tse khahlanong le PD-1) le FOLFOX bakeng sa kalafo ea pele ea bakuli ba nang le HER2 e mpe ea mpa kapa ea metastatic. kankere ea mokokotlo oa gastroesophageal. Liphetho tsa boithuto li ile tsa hlahisoa nehelanong ea molomo Sebokeng sa Selemo le Selemo sa Mokhatlo oa Amerika oa Patlisiso ea Kankere (AACR) New Orleans. Lintlha tse hlahisitsoeng li bontša hore phekolo ea motsoako oa TTX-030 ka kakaretso e ne e mamelloa hantle 'me e bontša matšoao a khothatsang a mosebetsi o khahlanong le hlahala.

"Lipalo tsa karabelo tse kenyellelitsoeng ho bakuli ba nang le lihlahala tse tlase tsa PD-L1 tse bonoang tlhahlobisong ena ea pele li khothatsa haholo ebile li ts'ehetsa bokhoni ba TTX-030 ho ama maemo a tlhokomelo ho bakuli ba nang le mofetše oa mala le oa gastroesophageal," ho boletse Zev Wainberg, MD. Moprofesa oa Bongaka ho UCLA le motsamaisi-'moho le UCLA GI Oncology Program. "Re lebelletse liphetho tse felletseng tekong ena le tsoelo-pele e tsoelang pele ea mokhoa ona o tšepisang oa kalafo."

Liphetho tsa pele tsa ts'ebetso le ts'ireletso li hlahisitsoe joalo ka ha ho khaotsoe ha data ea nakoana ea la 1 Hlakubele 2022. Kakaretso ea bakuli ba 44 ba ngolisitsoe. Bakuli ba mashome a mabeli a metso e tšeletseng (26) ba ne ba ntse ba le kalafo ea thuto, 'me nako e bohareng ea thuto e ne e le matsatsi a 214 (matsatsi a 8-464+). Har'a bakuli ba 40 ba sebetsang hantle, bakuli ba 21 (bakuli ba 25 ho kenyeletsa le ba sa tiisetsoang) ba fihletse karabelo e ntle ka ho fetisisa ea karabelo e sa fellang kapa e molemo ho kenyeletsa 4 CRs: ORR = 52.5% (62,5% ho kenyeletsa le ho sa tiisetsoa), le tekanyo ea ho laola maloetse = 92.5%. Bakuli ba mashome a mararo a metso e supileng (37) ba bakuli ba nang le ts'ebetso e nepahetseng ba ne ba tseba PD-L1 Combined Positive Score (CPS); litekanyetso tsa karabelo ho bakuli ba CPS ≥1 e ne e le 65% (77% ho kenyeletsoa e sa tiisetsoang).

Bakuli ba mashome a mabeli a metso e supileng ho ba 44 (61%) ba bile le bonyane ketsahalo e le 'ngoe e mpe (AE) ea sehlopha leha e le sefe se nkoang se amana le TTX-030 (tlhahlobo ea mofuputsi), ho kenyelletsa le bakuli ba 9 (20.5%) ba nang le Kereiti ea 3 / 4 AEs. Liketsahalo tse mpe li ne li lumellana ka kakaretso le tse bonoang ka tlhokomelo e tloaelehileng (chemotherapy hammoho le anti-PD-1).

"Lintlha tsa rona tse totobalitsoeng ho AACR li emetse liphetho tsa pele tse ts'episang tsa kliniki tsa anti-CD39 antibody ho bakuli ba nang le mofetše oa ka mpeng mme e ts'ehetsa karolo ea TTX-030 ho khutlisa khatello ea 'mele ea ho itšireletsa mafung ea adenosine," ho boletse Anil Singhal, Ofisiri e Moholo. "Re lebelletse tsoelo-pele e tsoelang pele ea thuto ena ea bongaka ea TTX-030, eo re lumelang hore e na le monyetla oa ho ntlafatsa haholo paradigm ea kalafo bakeng sa bakuli ba mofetše."

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...